Companies Team Up to Evaluate Combination of TG4001 with Avelumab

Transgene has entered a collaboration agreement with Merck KGaA and Pfizer to assess a combination drug product.

Transgene will sponsor a Phase I/II study of the drug candidate TG4001 in combination with avelumab for the treatment of human papilloma virus-positive head and neck squamous cell carcinoma (HNSCC), after failure of standard therapy.

The combination of TG4001 and avelumab aims to target two steps in the immune response to target cancer cells.